Wisconsin Federal Court Rules in Favor of ZELTIQ Aesthetics, Inc. in Case Against Brown Health Relaxation Station and Nouvelle

Wisconsin Federal Court Rules in Favor of ZELTIQ Aesthetics, Inc. in Case 
Against Brown Health Relaxation Station and Nouvelle Weight Loss
Centers 
Permanent Injunction Granted Against Wisconsin-Based Spa Misleading
Consumers by Performing Counterfeit CoolSculpting(R) Procedure 
PLEASANTON, CA -- (Marketwired) -- 06/02/14 --  ZELTIQ Aesthetics,
Inc. (NASDAQ: ZLTQ), a medical technology company focused on
developing and commercializing products utilizing its proprietary
controlled-cooling technology platform, today announced the United
States District Court, Eastern District of Wisconsin, ruled in favor
of ZELTIQ and granted a permanent injunction against Brown Health
Relaxation Station LLC, Nouvelle Weight Loss Centers and Melanie
Brown for trademark infringement, false advertising, false
designation of origin and unfair competition arising from the
Defendants' conduct with a counterfeit device and procedure.  
ZELTIQ is the exclusive global licensee of Cryolipolysis(R), the
proprietary and patented technology behind the aesthetic procedure
marketed as CoolSculpting(R). Cryolipolysis is the non-invasive
cooling of adipose tissue to induce lipolysis -- the breaking down of
fat cells -- to reduce body fat without damage to other tissues. The
CoolSculpting system developed by ZELTIQ is the only fat-freezing
technology cleared by the FDA for distribution and use in the United
States. The Defendants do not own a CoolSculpting system, nor are
they trained as an authorized provider of the CoolSculpting
procedure.  
In granting the injunction, the Court ruled that the Defendants
caused "irreparable harm" to ZELTIQ with their illegal marketing,
promotion and selling of the counterfeit "Freeze Sculpting"
treatments. The "Freeze Sculpting" device is not FDA cleared and has
not undergone any regulatory review or clinical testing. As a result
of the ruling, the Defendants are permanently enjoined from
misappropriating any of ZELTIQ's trademarks or Freeze Sculpting,
advertising the treatments or otherwise confusing consumers into
believing that they are associated with ZELTIQ or the CoolSculpting
procedure. Defendants are also required to turn the counterfeit
device over to ZELTIQ for inspection and/or destruction. The court
also awarded ZELTIQ its attorneys' fees an
d costs incurred in
bringing the federal court action. 
"We urge medical practices that are considering investing in
non-invasive fat reduction technology to make informed choices. We
also urge patients interested in the CoolSculpting procedure to seek
treatment only from authorized physician providers within the elite
network of CoolSculpting centers listed on our website," said Sergio
Garcia, ZELTIQ Senior Vice President, General Counsel and Corporate
Secretary.  
"ZELTIQ has invested years of research and millions of dollars to
build a reputation based on clinically proven safety and efficacy,
and we will vigorously protect that reputation and our intellectual
property rights from counterfeit devices not cleared by the FDA that
are trading on our good name," added Garcia. "When we learn about the
distribution, promotion or use of counterfeit devices and treatments
anywhere in the U.S., we take swift action such as the litigation we
initiated in the Federal District Court, Eastern District of
Wisconsin, to stop infringement of our intellectual property rights
and other related illegal activity." 
About ZELTIQ(R) Aesthetics, Inc.
 ZELTIQ Aesthetics, Inc. is a
medical technology company focused on developing and commercializing
products utilizing its proprietary controlled-cooling technology
platform. ZELTIQ's first commercial product, the CoolSculpting
system, is designed to selectively reduce stubborn fat that may not
respond to diet or exercise. The CoolSculpting procedure is based on
the scientific principle that fat cells are more sensitive to cold
than the overlying skin and surrounding tissues. It utilizes patented
technology of precisely controlled cooling to reduce the temperature
of fat cells in the treated area, which is intended to cause fat cell
elimination through a natural biological process known as apoptosis.
ZELTIQ developed the CoolSculpting procedure to safely, noticeably,
and measurably reduce the fat layer.  
MEDIA CONTACT: 
Marlo Rodman 
ZELTIQ
Public Relations Manager 
925-918-1190 
INVESTOR RELATIONS:
Patrick F. Williams
ZELTIQ
Senior Vice President and CFO
925-474-2500 
Nick Laudico
The Ruth Group for ZELTIQ
646-536-7030 
 
 
Press spacebar to pause and continue. Press esc to stop.